Blocking a protein that hijacks the immune system's checkpoints to allow tumor growth shows potential of an antibody-based treatment for brain cancer.
The researchers found that the protein FGL2 acted as a key "switch" to prevent tumors from being detected by the immune system and neutralized it by using anti-FGL2 antibody, curing four of the 17 infected mice.
"It is well-known that cancer evades immune surveillance by exploiting a series of editing mechanisms to avoid immune detection and eradication," said Shulin Li, professor at the University of Texas MD Anderson Cancer Center.
FGL2 modulates the immune system's "brakes" called checkpoints, as well as immune suppressive cells that stop the immune system's natural attack on cancer cells, the findings showed.
The study found that FGL2 increased tumor growth in mice by enhancing immune checkpoint gene expression.
The research team neutralized the protein by using an anti-FGL2 antibody.
"The average survival time in mice treated with the antibody was significantly longer than those receiving an alternative control antibody," Heimberger noted.
"Interestingly, four of 17 mice treated with FGL2 antibody were completely tumor free," Heimberger said.
The study team also found an association between levels of FGL2 expression and tumor aggressiveness. The results revealed that patients who had higher levels of FGL2 expression experienced a lower overall survival rate than patients with less FGL2 expression.
The results were published in the Journal of the National Cancer Institute.